This study aims to evaluate the effect of Acetyl-L-carnitine (ALCAR) in pre-frail older patients.
We scheduled 3 months of treatment and then 3 months of follow-up. A total of 92 subjects were selected from May, 2009 to July, 2017, in a randomized, observational, double-blind, placebo-controlled study. We scheduled 3 months of treatment and then 3 months of follow-up. ALCAR (oral 1.5 g/bis in die - BID) or placebo groups were used.
After the treatment, only the treated group displayed a decrease in C reactive protein (CRP) p < 0.001 and an increase in serum-free carnitine and acetylcarnitine (p < 0.05) in Mini-Mental state (MMSE) p < 0.0001 and 6-walking distance (p < 0.0001); ALCAR group vs. placebo group showed a decrease in HDL cholesterol and CRP (p < 0.01), an increase in MMSE score (p < 0.001) and in the 6-walking distance (p < 0.001).
ALCAR treatment delays the incidence and severity of onset of degenerative disorders of the elderly in prefrail subjects with improvement in memory and cognitive processes.
本研究旨在评估乙酰-L-肉碱(ALCAR)在体弱前期老年患者中的作用。
我们安排了3个月的治疗和3个月的随访。从5月共选取92名受试者,2009年7月,2017年,在一个随机的,观察,双盲,安慰剂对照研究。我们安排了3个月的治疗和3个月的随访。使用ALCAR(口服1.5g/bis,在die-BID中)或安慰剂组。
治疗后,仅治疗组表现出C反应蛋白(CRP)p<0.001降低,而无血清肉碱和乙酰肉碱(p<0.05)在迷你精神状态(MMSE)p<0.0001和6步行距离(p<0.0001)中增加;ALCAR组vs.安慰剂组显示HDL胆固醇和CRP降低(p<0.01),MMSE评分(p<0.001)和6步行距离(p<0.001)的增加。
ALCAR治疗延缓了老年患者退行性疾病的发病率和严重程度,改善了记忆和认知过程。